
ESOCAP AG PROFILE FEATURED IN NATURE BIOPHARMA DEALMAKERS

Basel, Switzerland, July 28, 2021

The feature in the latest issue of the renowned Nature Research publication gives an insightful overview of EsoCap's company profile and the current development stage of their novel platform technology for the world's first local treatment of the esophagus.

The article explains what makes the innovative application technology so unique. "The advanced phase of development is just the start of the story", said Isabelle Racamier, EsoCap CEO. "EsoCap is building a business strategy towards partnering. The EsoCap platform will be valuable for biopharmaceutical companies already working in gastroenterology, immunology or oncology, as well as for contract manufacturers."

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland. EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique topical drug delivery platform. Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve, due to ultra-short transit times, with less than two seconds from mouth to stomach.

EsoCap owns a unique drug delivery platform, allowing topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract, enabling esophageal mucosa contact times never seen before.

For more information, please visit www.esocap-biotech.com.



EsoCap

About Biopharma Dealmakers

Biopharma Dealmakers—a Nature Research publication—brings together life scientists, biotech and pharmaceutical professionals, and investors from across the globe. Biopharma Dealmakers provides timely information and analysis on deal-making activity and supports the development of business partnerships. Biopharma Dealmakers is free to access at www.nature.com/biopharmdeal. Print issues are distributed to the readers of **Nature Biotechnology** and **Nature Reviews Drug Discovery**.

Biopharma Dealmakers offers readers themed editorial features that provide insights into deal-making and industry trends. Regular editorial content includes biopharma deal round-ups, financing news and a collection of 'business of science' articles from the Nature Research catalogue.

Contact:

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com